Jefferson Shreve sold Vaxcyte Inc (NASDAQ: PCVX)
Jefferson Shreve (R-IN), a U.S. Representative, has disclosed 1 trade in Vaxcyte Inc (PCVX) since 2025, a single sale, worth an estimated $33K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Jefferson Shreve sold $15,001 - $50,000 of Vaxcyte Inc (NASDAQ: PCVX) on March 5, 2025. Since that trade, PCVX is down -24.27% against the S&P 500 up +29.05%, an outperformance of -53.32%.
Data updated
Jefferson Shreve's PCVX trades vs the price
PCVX is down -24.27% since Jefferson Shreve sold on March 5, 2025, versus +29.05% for the S&P 500.
Performance since this trade
All Jefferson Shreve PCVX trades
Jefferson Shreve & PCVX trading FAQ
Is it legal for Jefferson Shreve to trade Vaxcyte Inc (PCVX) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Vaxcyte Inc (PCVX), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Jefferson Shreve sell PCVX?
Jefferson Shreve disclosed a sale of $15,001 - $50,000 of Vaxcyte Inc (PCVX) on March 5, 2025, according to public STOCK Act filings.
How has PCVX performed since Jefferson Shreve's trade?
Since Jefferson Shreve sold PCVX on March 5, 2025, the stock is down -24.27%, versus +29.05% for the S&P 500 over the same period, an outperformance of -53.32%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional PCVX trades?
Quantellect tracks every disclosed congressional trade in Vaxcyte Inc (PCVX) on the Vaxcyte Inc congressional trading page, which aggregates filings across all members of Congress.
Jefferson Shreve's PCVX tradesAll congressional filings for Vaxcyte IncJefferson Shreve's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.